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Introduction  
Nonalcoholic fatty liver disease (NAFLD) is one of  common 
causes of  chronic liver disease, with increasing prevalence up to 
20-30% worldwide [1]. NAFLD represents a group of  condi-
tions ranging from simple steatosis, nonalcoholic steatohepati-
tis (NASH), and cirrhosis [2]. Because the central pathogenesis 
of  NAFLD is insulin resistance, NAFLD is considered to be a 
hepatic manifestation of  metabolic syndrome (MS) [3]. In addi-
tion, NAFLD is closely linked to cardiovascular risk factors such 
as Type 2 diabetes, dyslipidemia and central obesity, which are 
components of  metabolic syndrome [4, 5].  MS is related to ath-
erosclerosis, cardiovascular disease, and as a result, increasing the 
development of  diabetes and mortality of  cardiovascular disease 
[6-8]. Many studies have shown the association between NAFLD 
and MS. A prospective observational study in Japan has identi-
fied MS as a strong predictor of  NAFLD [9]. A recent study has 
found that the number of  MS component was useful in predict-
ing NAFLD [10]. However, a few studies have examined the ef-
fect of  NAFLD the development of  MS. Subjects with NAFLD 
and elevated liver enzyme was at an increased risk of  developing 
MS [11]. A recent prospective cohort study showed that NAFLD 
was an independent risk factor for MS [12]. However, there is no 
data evaluating the development MS according to the severity of  
NAFLD including suspected simple steatosis and NASH based 
on general population. Therefore, the aim of  this study was to 
determine the relationship between clinical severity of  NAFLD 
according to ALT levels and the development of  MS.
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Patients and Methods
Study population
A retrospective cohort study was conducted to evaluate the as-
sociation between NAFLD and the development of  MS. The 
participants who underwent abdominal ultrasonography (US) 
and blood samplings at the Seoul National University Hospital 
Gangnam Healthcare Center, Seoul, Korea for routine health 
check-ups both in 2005 and 2010 were recruited. Most of  the 
study population paid voluntarily for their health check-ups and 
some of  them were supported by their company. 184 subjects 
positive for hepatitis B virus, 44 with positive hepatitis C virus, 
754 subjects with alcohol consumption (>20 g/day for males and 
>10 g/day for females) and other hepatitis history were excluded. 
Among the 3,460 subjects enrolled, 732 subjects were excluded 
due to pre-existing MS. Finally, 2,728 subjects met inclusion crite-
ria. This study was approved by the Institutional Review Board of  
the Seoul National University Hospital with a waiver of  informed 
consent.
Clinical and laboratory assessments
Each subject completed a past medical history questionnaire and 
received an anthropometric assessment and laboratory and radio-
logic tests on the same day. Body weight and height were measured 
using a digital scale, and body mass index (BMI) was calculated by 
dividing weight (kg) by the square of  height (m2). Waist circumfer-
ence was measured at the midpoint between the lower costal mar-
gin and the anterior superior iliac crest by a well-trained person 
using a tape. Systolic blood pressure and diastolic blood pressure 
were measured twice, and the mean values were reported. The 
laboratory tests included serum alanine aminotransferase (ALT), 
total cholesterol, triglyceride, high density lipoprotein (HDL) cho-
lesterol, fasting glucose, hepatitis B surface antigen and antibody 
to hepatitis C virus. Blood samples were collected before 10:00 
AM after a 12-h overnight fast. All laboratory tests were carried 
out using standard laboratory methods.
Definitions
The presence of  diabetes mellitus was defined as either a fasting 
serum glucose ≥ 126 mg/dL or use of  anti-diabetic medication. 
The presence of  hypertension was defined as having a systolic 
blood pressure ≥ 140 mmHg or diastolic blood pressure ≥90 
mmHg or use of  anti-hypertensive medication. Current smok-
ers were defined as having smoked at least 1 cigarette/day during 
the previous year. Former smokers were defined as prior regular 
cigarettes smoking [13]. Abnormal liver enzyme levels were based 
on ALT elevation over the strict cut-off  point based on the up-
dated definitions by Prati et al. 30 IU/L for men and 19 IU/L for 
women [14].
NAFLD was defined as the presence of  fatty liver disease as de-
termined by ultrasonography in the absence of  the following: 1) 
seropositivity for hepatitis B surface antigen or antibody to hepa-
titis C virus, 2) excessive alcohol intake (> 20g/day for males and 
>10 g/day for females), 3) other causes of  liver disease, and 4) 
medications known to produce fatty liver disease.
MS was diagnosed when three or more of  the five components 
were present, that is, (1) central obesity [waist circumference as 
defined by the Regional Office for the Western Pacific Region of  
the World Health Organization (WPRO) criteria, >90 cm (men) 
or >80 cm (women)]; (2) a triglyceride level ≥150 mg/dL (3) 
HDL-C <40 mg/dL (men) or <50 mg/dL (women); (4) fasting 
glucose ≥100 mg/dL or treatment for diabetes; (5) arterial pres-
sure ≥130/85 mmHg or treatment for hypertension [15].
US assessments
US examination of  the liver was performed by experienced radi-
ologists who were unaware of  the clinical information. The diag-
nosis of  FL was performed by ultrasonography (Acusion, Sequi-
oa 512, Siemens, Mountain View, CA) using previously described 
standardized criteria [16].
Statistical analysis
Comparisons of  continuous variables between the two groups 
were performed with the Student’s t-test, and categorical variables 
were compared using the chi-square test or Fisher’s exact test. 
Variables that were statistically significant by univariate analysis 
and known risk factors were added to a multiple logistic regres-
sion model to identify independent predictors of  the presence of  
NAFLD.  Statistical analysis was performed with SPSS 19.0 (SPSS 
Inc.; Chicago, IL, USA). P-values <0.05 were considered statisti-
cally significant.
Results
Baseline characteristics
A total of  2,728 subjects were finally analyzed. Their mean age 
was 47.5 ± 9.7 years and 50.4% were male. The anthropometric, 
clinical and laboratory characteristics of  the subjects are shown in 
Table 1. FL with normal ALT was found in 369 (13.5%) and FL 
with elevated ALT in 328 (12.0%) subjects at baseline. BMI, waist 
circumference, ALT, and triglyceride level were higher in patients 
with NAFLD compared to the control group (p<0.001).
Development of  the metabolic syndrome
During 5 years of  follow-up between 2005 and 2010, 582 (21.3%) 
incident cases of  MS developed. The incidence of  MS was higher 
in patients with NAFLD compared to control group (41.2% in 
FL with elevated ALT, 34.7% in FL with normal ALT and 15.7% 
in control, p<0.001). Subjects who developed MS on follow-up 
were older with greater central obesity, dyslipidemia, and blood 
pressure at the time of  baseline assessment compared to those 
who did not developed MS (p<0.001, Table 2).
To examine incident MS according to the NAFLD categories 
(control, FL with normal ALT and FL with elevated ALT), analy-
sis was stratified according to baseline NAFLD categories (Ta-
ble 3). In age and sex adjusted model, odds ratio (OR) and 95% 
confidence (CI) interval for MS increased according to the de-
gree of  NAFLD [1.99 (1.54−2.59) in FL with normal ALT and 
3.09 (2.38−4.01) in FL with elevated ALT, p<0.001]. These asso-
ciations were attenuated, but still remained significant, even after 
further adjustments for covariates, such as BMI, smoking, central 
obesity, hypertension, glucose, triglyceride and high-density lipo-
protein cholesterol (model 2). [OR (95% CI), 1.29 (0.97−1.71) in 
FL with normal ALT and 1.54 (1.18−1.33) in FL with elevated 
ALT, p=0.01].
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Table 1. Comparison of  baseline characteristics in nonalcoholic fatty liver disease with or without elevated alanine                 
aminotransferase versus control.
Control
(n=2,031)
FL with normal 
ALT (n=369)
FL with elevated 
ALT (n=328)
p for 
trend
Age, years 47.0 ± 9.7 49.8 ± 9.2 48.1 ± 9.6 <0.001
Male sex, % 843 (41.5) 292 (79.1) 239 (72.9) <0.001
Smoking, % 252 (12.4) 74 (20.1) 71 (21.6) <0.001
Body mass index, kg/m2 21.9 ± 2.7 24.1 ± 2.1 22.6 ± 2.9 <0.001
Waist circumference, cm 80.9 ± 8.0 85.6 ± 5.4 87.2 ± 9.5 <0.001
ALT, IU/L 19.8 ± 11.9 20.1 ± 5.6 44.2 ± 23.0 <0.001
Fasting glucose, mg/dL 94.8 ± 11.3 102.2 ± 18.8 100.8 ± 15.8 <0.001
Triglycerides, mg/dL 83.5 ± 38.3 114.9 ± 51.7 120.5 ± 67.4 <0.001
HDL cholesterol, mg/dL 58.0 ± 13.2 51.0 ± 10.7 50.9 ± 11.4 <0.001
CRP, mg/dL 0.08 ± 0.21 0.09 ± 0.30 0.09 ± 0.23 0.316
Hypertension, % 186 (9.6) 56 (15.2) 50 (15.2) <0.001
5_year metabolic syndrome 
development
319 (15.7) 128 (34.7) 135 (41.2) <0.001
Data are presented as the mean ± SD
P-value by ANOVA-test for continuous variables and Chi square test for categorical variables
ALT, alanine aminotransferase; CRP, C-reactive protein; FL, fatty liver; HDL, high density lipoprotein;
Table 2. Baseline characteristics associated with development of  metabolic syndrome over 5-year follow up period.
MS absent at follow-
up (n=2,146)
MS present at follow-up 
(n=582)
p
Age, years 46.5 ± 9.4 51.3 ± 9.7 <0.001
Male sex, % 959 (44.7) 415 (71.3) <0.001
Smoking, % 273 (12.7) 74 (20.1) <0.001
Body mass index, kg/m2 22.1 ± 2.8 24.2 ± 2.7 <0.001
Waist circumference, cm 80.5 ± 7.9 86.1 ± 8.8 <0.001
ALT, IU/L 21.5 ± 14.7 27.2 ± 16.9 <0.001
Fasting glucose, mg/dL 94.8 ± 11.2 103.1 ± 18.3 <0.001
Triglycerides, mg/dL 87.4 ± 44.1 109.6 ± 53.5 <0.001
HDL-cholesterol, mg/dL 57.0 ± 13.4 53.4 ± 11.1 <0.001
Hypertension, % 141 (6.6) 151 (25.9) <0.001
MS, metabolic syndrome; ALT, alanine aminotransferase; HDL, high density lipoprotein
Table 3. Age- and sex-adjusted and multivariable analyses of  risk of  metabolic syndrome in nonalcoholic fatty liver disease 
with or without elevated ALT versus control.
Control
(n=2,031)
FL with normal 
ALT (n=369)
FL with elevated 
ALT (n=328)
p for 
trend
Subjects who developed 
MS, n (%) 319 (15.7) 128 (34.7) 135 (41.2) <0.001
Adjusted OR (95% CI)
Model 1 1 (reference)
1.99 3.09
<0.001
 (1.54−2.59)  (2.38−4.01)
Model 2, 1 (reference)
1.29 1.54
0.01
 (0.97−1.71)  (1.18−1.33)
Model 1: adjusting for age and sex, Model 2: adjusting for age, sex, BMI, smoking, central obesity, hypertension, glucose, triglyceride 
and high-density lipoprotein. MS, metabolic syndrome; ALT, alanine aminotransferase; FL, fatty liver; OR, odds ratio; CI, confidence 
interval
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We next investigated whether serum ALT threshold associated 
with the development of  MS. Figure 1 illustrates that higher base-
line ALT levels were significantly correlated with the development 
of  MS in the subjects with NAFLD. Table 4 shows the effect sizes 
of  NAFLD among groups divided according to each metabolic 
component for the development of  MS. The effect of  NASH on 
the development of  MS was comparable to other components of  
MS except hypertension.
Discussion
The study showed that incidence of  MS was increased in NAFLD 
patients according to the NAFLD categories (control, FL with 
normal ALT and FL with elevated ALT). These findings suggest 
an independent role of  NAFLD in the development of  MS. Con-
sistent with our study, Adams et al. [11] reported that subjects 
with NAFLD and elevated ALT levels are at increased risk of  
developing MS. However, NAFLD was not a significant predictor 
of  the development of  MS in multivariate analysis in the study 
[11]. In addition, subjects with NAFLD and normal ALT levels 
were not included in the study, because definition of  NAFLD 
was based only ALT levels. A case-control study [17] has shown 
that the presence of  NAFLD may predict the development of  
metabolic disorders due to insulin resistance. However, the defi-
nition of  metabolic disorders is was not clear and there was no 
data about NASH [17]. A recent prospective cohort study showed 
that the risk of  MS independently increased according to the de-
gree of  NAFLD [12]. In this study, the subjects were confined 
to male and the degree of  NAFLD was categorized by only US. 
Most studies using US refer to a three- score system for FL (mild, 
moderate and severe) based on echogenity of  the liver [18, 19]. 
Although US is an established tool as a screening modality with 
acceptable sensitivity and specificity in detecting FL, US has lim-
itations in grading the severity of  NAFLD [20]. First, because 
of  operator-dependency of  US imaging, it is inaccurate in the 
quantification of  fat accumulation. A retrospective study showed 
that the mean intra-observer agreement for severity of  FL ranged 
from 55% to 68% [21]. Second, it is difficult to distinguish simple 
steatosis from steaohepatitis or fibrosis [22] as these have similar 
sonographic findings.
The presence of  NAFLD on sonographic finding does not always 
indicate elevated ALT level. Only 16.5% of  women and 14.5% of  
men above the 75th percentiles of  ALT ( ≥19 for women and ≥23 
for men) showed sonography findings of  NAFLD [23]. Wang et 
al. [24] showed that coexistence of  NAFLD and elevated ALT 
(>30) were associated with insulin resistance in young Han males, 
providing evidence of  a relationship between NAFLD and elevat-
ed ALT level. In this study, we stratified subjects with NAFLD ac-
cording to the ALT levels; NAFLD with normal ALT vs. NAFLD 
with elevated ALT (>30/19), which may reflect the presence of  
NASH, and development of  MS was significantly higher accord-
ing to the degree of  NAFLD. As a result, the odds ratio of  NASH 
on the development of  MS was comparable to other components 
of  MS, which suggests the role of  a NASH as one component 
of  MS. Using similar criteria for NAFLD categories to our study, 
Sung et al. [25] have shown that overall cardiovascular risk was 
significantly greater in NASH, defined as steatosis and an in-
creased serum ALT, than either simple steatosis or raised ALT 
alone. Baumeister et al. [26] have identified that subjects with so-
Figure 1. Cumulative probability for the development of  metabolic syndrome in 5-year follow-up in subjects with nonalco-
holic fatty liver disease according to baseline ALT levels.
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Table 4. The effect size of  nonalcoholic fatty liver disease and groups divided according to each metabolic component for 
the development of  metabolic syndrome. (Age, sex, body mass index and smoking adjusted).
OR (95% CI)
Glucose > 100 2.00 (1.62−2.49)
Obesity 1.42 (1.08−1.88)
Hypertriglycemia 1.55 (1.13−2.11)
Low HDL 1.82 (1.31−2.54)
Hypertension 3.01 (2.42−3.74)
FL with normal ALT 1.47 (1.12−1.93)
FL with elevated ALT 1.84 (1.39−2.44)
ALT, alanine aminotransferase; OR, odds ratio; CI, confidence interval; HDL, high density lipoprotein; FL, fatty liver
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nographic FL and increased serum ALT levels had higher overall 
health care cost at 5-year follow up. These findings suggest that 
NAFLD categories used in this study are useful for predicting the 
prognosis of  NAFLD.
In our study, development of  MS was increased according to the 
increased ALT levels in subjects with NAFLD. The findings are 
in accordance with the two previous studies [27, 28]. An Austral-
ian population-based cohort study has found a strong association 
between ALT level and MS independent of  insulin resistance [27]. 
Another study has suggested the role of  ALT as an indicator for 
the 6-year risk of  MS development in a general population of  
middle-aged Caucasians [28]. However, presence of  NAFLD was 
not considered in these studies.
The strength of  our study is that this is the first to determine 
the causal relationship between the severity of  NAFLD and the 
development of  MS providing substantial duration of  follow-up. 
Moreover, the subjects in our study are representative of  the gen-
eral population due to the nature of  a health check-up. Finally, the 
clinical diagnosis of  NAFLD and suspected NASH used in this 
study may have implications for clinicians managing patients in 
the primary care center.
There are limitations of  our study. First, hepatic sonography is 
used as a diagnostic tool for NAFLD, and this method cannot 
diagnose a small fatty infiltration below 30%. However, because 
of  its relatively high sensitivity up to 84.8% and specificity up 
to 93.6%, hepatic ultrasound is widely used a diagnostic test for 
NAFLD [29, 30]. Although a biopsy was needed for grading for 
severity of  NAFLD, we categorized NAFLD groups according 
to ALT levels. Actually, biopsies were not available in all subjects 
with NAFLD, and this grouping has been generally accepted. Sec-
ond, there might be a selection bias, because this study was per-
formed at a single health screening center and we did not evaluate 
whether the subjects were treated during the study period because 
of  a retrospective design. Third, we cannot identify the effect of  
insulin resistance because there was no data regarding insulin lev-
els in this study. However, a previous study in China established 
the association between NAFLD with elevated ALT with insulin 
resistance [24], supporting our results.
Conclusion
We have demonstrated that the development of  MS is significant-
ly increased according to the clinical severity of  NAFLD during a 
5-year follow-up. These findings have implications in the clinical 
availability of  NAFLD as a predictor of  MS.
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